Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DepoCyte prophylaxis for central nervous system relapse in standard-risk acute lymphoblastic leukemia
2009-009422-92Phase 3Terminated
- Sponsor
- Fundación PETHEMA
- Start
- Feb 2010
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of liposomal cytarabine in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Fundación PETHEMA. Primary endpoints: Frequency of neuromeningeal relapse and Actuarial probability of central nervous system relapse. Started Feb 2010; status: terminated.
02
Drugs
liposomal cytarabine
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2009-009422-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009422-92.